<h4>Background</h4>In 2018, France withdrew reimbursement for cholinesterase inhibitors (ChEIs) in Alzheimer's disease, citing modest efficacy, lack of long-term benefit, and safety concerns. Here, BCHE is linked to Alzheimer disease.